Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $88.73 USD
Change Today +6.39 / 7.76%
Volume 900.2K
HTWR On Other Exchanges
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

heartware international inc (HTWR) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/13/15 - $95.59
52 Week Low
12/11/14 - $69.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

heartware international inc (HTWR) Related Businessweek News

No Related Businessweek News Found

heartware international inc (HTWR) Details

HeartWare International, Inc., a medical device company, designs, develops, manufactures, and markets miniaturized implantable heart pumps or ventricular assist devices (VAD) for the treatment of advanced heart failure in the United States, Germany, and internationally. It offers HeartWare Ventricular Assist System, which comprises a VAD or blood pump, patient accessories, and surgical tools designed to provide circulatory support for patients in the advanced stage of heart failure. The company is also developing the MVAD, a miniaturized blood pump intended for chronic heart failure patients; and SYNERGY Circulatory Support System, a partial support system designed to treat less sick, ambulatory, chronic heart failure patients who are not yet inotrope-dependent. The company markets its products directly to clinicians and medical facilities, as well as through medical device distributors. HeartWare International, Inc. is headquartered in Framingham, Massachusetts.

585 Employees
Last Reported Date: 03/2/15

heartware international inc (HTWR) Top Compensated Officers

Chief Executive Officer, President, Managing ...
Total Annual Compensation: $558.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $334.6K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $331.6K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $329.2K
Senior Vice President of Research & Developme...
Total Annual Compensation: $276.4K
Compensation as of Fiscal Year 2014.

heartware international inc (HTWR) Key Developments

Heartware International Inc. to Report Q2, 2015 Results on Jul 30, 2015

Heartware International Inc. announced that they will report Q2, 2015 results at 8:00 AM, US Eastern Standard Time on Jul 30, 2015

Heartware International Inc., Q2 2015 Earnings Call, Jul 30, 2015

Heartware International Inc., Q2 2015 Earnings Call, Jul 30, 2015

Heartware International Inc. Announces Commencement of its MVAD System CE Mark International Clinical Trial

Heartware International Inc. announced commencement of its MVAD System CE Mark international clinical trial. The first patients receiving HeartWare's next-generation MVAD Pump were implanted at the Freeman Hospital in Newcastle upon Tyne, England, and at the Medical University AKH Vienna in Austria. The MVAD Pump is a heart pump that supports a wide range of flows to enable circulatory support for patients with advanced heart failure. The MVAD Pump was designed with a low shear stress impeller and optimal blood flow paths, which together are expected to result in improved hemodynamic performance. In addition, the MVAD System incorporates a pulsatility algorithm called the qPulse™ Cycle that allows physicians to customize the device for each patient, providing four pulse settings designed to enhance aortic valve function and reduce chronic bleeding events. The MVAD Pump, which weighs only 78 grams and displaces 22 cc of volume, has a steerable sewing ring, which enables clinicians to position the inflow cannula to facilitate optimal blood flow into the pump. The integrated Pal controller and battery system includes a touch-screen display and two sizes of small, light-weight, snap-on batteries. The CE Mark trial is a multicenter, prospective, non-randomized, single-arm trial that evaluates the clinical safety and performance of the HeartWare MVAD System for the treatment of advanced heart failure. The trial will enroll 60 patients at 11 sites in the United Kingdom, Austria, Australia, France and Germany (pending final regulatory approval from BfArM). In the trial, patients will be implanted with the MVAD Pump via sternotomy or thoracotomy, and the device will be evaluated for short- and long-term use. The primary endpoint is survival at six months. HeartWare has submitted to the U.S. Food and Drug Administration (FDA) an Investigational Device Exemption (IDE) seeking approval to commence an MVAD System clinical trial in the United States. Health Canada is also reviewing a submission for a 15-patient, three-center study, which is expected to commence later this year.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HTWR:US $88.73 USD +6.39

HTWR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ABIOMED Inc $77.26 USD +1.64
Getinge AB kr209.30 SEK -0.60
Sunshine Heart Inc $3.00 USD -0.10
Teleflex Inc $133.40 USD -6.86
Thoratec Corp $63.29 USD +0.16
View Industry Companies

Industry Analysis


Industry Average

Valuation HTWR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.0x
Price/Book 7.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEARTWARE INTERNATIONAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at